Previous Pause Next
Home >> News Center >> Research Frontiers >> Stem Cells >>
Cryo-Cell Recognized by Tampa Bay Biztech Innovation Summit PDF Print E-mail
User Rating :  / 0
Tuesday, 01 March 2011 01:12

Cryo-Cell International, Inc. (OTC Bulletin Board Symbol: CCEL) (the “Company”), one of the world’s largest and most established family cord blood banks and an industry leader of innovative stem cell solutions, today announced that the Company has been selected as a finalist in the category of “Innovation of the Year” at the inaugural BizTech Innovation Summit hosted by the Tampa Bay Business Journal and the Tampa Bay Technology Forum. Winners will be named at the BizTech Innovation Summit on March 17th at the Tampa Convention Center.

Cryo-Cell first launched its Célle(SM) service in 2007, and it is a potential game changer to the cord blood banking industry. The Company discovered that stem cells harvested from menstrual blood are proven to be a rich source of undifferentiated stem cells which proliferate rapidly and have the ability to become many different types of cells such as cardiac, neural, bone, fat and cartilage. These stem cells are a potential source for promising regenerative therapies that may possibly treat debilitating diseases such as diabetes, heart disease and stroke in the future. Célle is the first and only service of its kind in the world empowering women to collect and cryopreserve stem cells from their own menstrual flow. Célle is available as a “Protect Baby, Protect Mom” (SM) bundle in combination with Cryo-Cell’s signature U-Cord(SM) umbilical cord blood service and as a standalone service.

"We believe that Célle technology has the potential to become the holy grail of regenerative medicine,” stated Mercedes A. Walton, Cryo-Cell’s chairman and chief executive officer. "Cryo-Cell has successfully executed an unprecedented research and development (R&D) collaborative business model based on the Company’s proprietary Célle technology with eleven global research partners since 2007. During 2010, Célle technology development progressed significantly. We anticipate that the Company’s expansive pipeline of R&D initiatives may include some very exciting prospects for future clinical therapies that may possibly catapult Cryo-Cell’s global leadership in stem cell innovation. Cryo-Cell is truly honored to be recognized by the Tampa Bay BizTech Innovation Summit as an awards finalist for “Innovation of the Year”.

During 2010, Cryo-Cell continued to make significant progress in advancing collaborative research partnerships to potentially develop a broad range of regenerative therapeutic applications utilizing Cryo-Cell’s patent-pending menstrual stem cell technology for possible future treatment. In April 2010, Cryo-Cell announced results of a study published in the cover article of the peer-reviewed journal Stem Cells and Development that demonstrates the potential of stem cells harvested from menstrual blood to be utilized as a possible source for stem cell therapies to treat stroke and other central nervous system disorders. The study was conducted by researchers at Cryo-Cell, the University of South Florida, Saneron-CCEL Therapeutics and the Medical College of Georgia.

Under the terms of the Célle scientific collaboration agreements that are independently-funded by the Company’s respective research partners, Cryo-Cell is expected to own 50% of the intellectual property associated with potential breakthrough therapies that may emerge from a diverse spectrum of R&D initiatives. In August 2010, the Company executed and announced an R&D collaboration agreement with Monash University in Australia, one of the largest and most established global leaders in stem cell innovation to conduct pre-clinical studies using Cryo-Cell’s proprietary Célle technology to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis. During the same month, Cryo-Cell announced that S-Evans Biosciences (SEB), the Company’s exclusive Célle menstrual stem cell technology license partner in China opened a new state-of-the-art laboratory operation and R&D facility located in a Hi-Tech park designated to become an epicenter for stem cell and genomics R&D; cellular therapies and stem cell cryopreservation services. Currently, SEB is conducting three pre-clinical studies for heart disease, type I diabetes and liver disease utilizing menstrual stem cells prepared in SEB and recently reported that the preliminary data are encouraging.

About BizTech Innovation Summit

BizTech is hosted by the Tampa Bay Business Journal and the Tampa Bay Technology Forum and will bring together local area businesses and technology vendors for this first annual event. The summit will kick off with an expo featuring exhibitors providing products and/or services covering areas such as software, hardware, consulting, IT, telecommunications, web services, mobile applications, and much more. The expo will be followed by an awards luncheon honoring Tampa Bay area businesses for their true innovation in key tech sectors, in social media, in collaboration with non-tech clients and for chief executive leadership.

About Cryo-Cell International, Inc.

Based in Oldsmar, Florida, with over 230,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2008 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. In November 2007, the Company launched Célle(SM) (pronounced “C-L”), the world’s first-ever commercial service allowing women to cryopreserve their own menstrual stem cells. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL begin_of_the_skype_highlighting              1-800-STOR-CELL      end_of_the_skype_highlighting (1-800-786-7235 begin_of_the_skype_highlighting              1-800-786-7235      end_of_the_skype_highlighting) or visit www.cryo-cell.com.

About Célle

The Célle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com.

source:http://www.onlineprnews.com

 
FairExcellent 

Add comment  |   Add to my library  |  Forward this article

login to leave comment